Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



The 1 Biotech Event You Can't Miss This Week

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

We may have averted a disaster of Mayan-gantic proportions, and Christmas is just around the corner, but that doesn't mean that clinical data or the Food and Drug Administration is going to take any time off. Although we have no earnings data to mull over this week, all eyes are going to be turned to the biotech sector, awaiting the FDA's decisions on Johnson & Johnson's (NYSE: JNJ  ) multidrug resistant, pulmonary tuberculosis drug, Bedaquiline, before or by Dec. 29.

The drug itself has excelled in midstage studies, and J&J subsidiary Janssen Pharmaceuticals is hoping that the FDA will grant Bedaquiline accelerated approval, given that no new pathways of treating MDR tuberculosis has been approved in roughly 40 years.

Janssen received priority-review status for Bedaquiline in September, following two phase 2 trials that covered two separate dosing regimens followed by a year to 18 months of standard therapy.

In late November, the FDA drug panel voted 18-0 in favor of recommending approval for Bedaqualine; however, panel members were decidedly mixed on its safety efficacy, choosing to vote to recommend the drug by a sum of 11-7. At the heart of panel members' concerns was a midstage subgroup featuring 79 patients, of which 10 died, compared with just two of the 81 patients taking the placebo. Some panel members pointed out that elevated levels of specific liver enzymes could signal the potential for liver toxicity. In addition, patients taking the experimental drug also demonstrated increases in their QT interval, leading panel members to believe that heart irregularities could arise while taking the drug.

The truth, though, is that beyond the standard treatments such as Rifadin, offered by Sanofi (NYSE: SNY  ) and combined with other TB agents, there hasn't been a big advance in treatment options, side effects, or efficacy in TB, or MDR-TB, in a long time. That could go a long way into determining whether Bedaquiling gets approved -- although it may not save the drug from a black box warning label.

In the meantime, a consortium of big pharmaceutical companies, including AstraZeneca (NYSE: AZN  ) , Eli Lilly (NYSE: LLY  ) , Abbott Laboratories (NYSE: ABT  ) , and Sanofi, to name a few, have joined forces with the Bill & Melinda Gates Foundation to launch the TB Drug Accelerator, or TBDA, program. The goal is to have five preclinical candidates with treatment-shortening potential within five years, and, while potentially putting a damper on Bedaquiline sales over the long term, could mean a big boost in treatment efficacy for the South Carolina Department of Health and Environmental Control's figure of one-third of the world's population that is infected with TB .

In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Critics think the company, offering everything from baby powder to biologics, has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand-new premium report on Johnson & Johnson. To claim your copy, simply click here now for instant access.

Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2167384, ~/Articles/ArticleHandler.aspx, 10/25/2016 3:24:21 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,166.09 -56.94 -0.31%
S&P 500 2,142.86 -8.47 -0.39%
NASD 5,279.87 -29.96 -0.56%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 3:08 PM
JNJ $113.93 Up +0.32 +0.28%
Johnson and Johnso… CAPS Rating: ****
ABT $40.19 Down -0.23 -0.56%
Abbott Laboratorie… CAPS Rating: *****
AZN $29.76 Down -0.33 -1.08%
AstraZeneca CAPS Rating: ****
LLY $77.68 Up +0.11 +0.14%
Eli Lilly and Co. CAPS Rating: ***
SNY $37.37 Down -0.39 -1.03%
Sanofi CAPS Rating: *****